Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Performance

GILD traded down $1.18 during trading hours on Friday, hitting $156.19. The company’s stock had a trading volume of 7,770,853 shares, compared to its average volume of 5,976,056. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $160.51. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $193.67 billion, a PE ratio of -58.50 and a beta of 0.31. The company has a 50-day simple moving average of $147.19 and a 200 day simple moving average of $137.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
• Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
• Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts
• Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing

Analyst Ratings Changes

Several equities analysts have commented on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a report on Thursday, October 8th. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Finally, Bank of America reiterated a “buy” rating and set a $164.00 price objective on shares of Gilead Sciences in a research note on Monday, October 12th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.33.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the fourth quarter valued at $25,000. Persistent Asset Partners Ltd bought a new position in shares of Gilead Sciences during the 2nd quarter valued at $25,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences in the second quarter worth $25,000. Wealth Preservation Advisors LLC boosted its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Wiser Advisor Group LLC acquired a new position in Gilead Sciences during the second quarter worth $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.